

## **Predictmedix Inc.**

Condensed interim consolidated financial statements

For the three months ended April 30, 2022 and 2021

(Unaudited - expressed in Canadian Dollars)

### **NOTICE TO READER**

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the interim financial statements have not been reviewed by an auditor.

The accompanying unaudited consolidated interim financial statements have been prepared by and are the responsibility of the management.

The Company's independent auditor has not performed a review of these consolidated interim financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

**PREDICTMEDIX INC.**  
**CONDENSED INTERIM FINANCIAL STATEMENTS**  
**THREE MONTHS ENDED APRIL 30, 2022 AND 2021**  
**(Unaudited - Amounts expressed in Canadian Dollars)**

**TABLE OF CONTENTS**

	<b>Page No</b>
<a href="#">Cover</a>	
<a href="#">Index</a>	<a href="#">1</a>
<a href="#">Condensed Consolidated Interim Statements of Financial Position as at April 30, 2022 (unaudited) and January 31, 2022 (audited)</a>	<a href="#">2</a>
<a href="#">Condensed Consolidated Interim Statements of loss and Comprehensive loss for the three months ended April 30, 2022 and April 30, 2021 (unaudited)</a>	<a href="#">3</a>
<a href="#">Condensed Consolidated Interim Statements of Changes in Equity for the three months ended April 30, 2022 and April 30, 2021 (unaudited)</a>	<a href="#">4</a>
<a href="#">Condensed Consolidated Interim Statements of Cash Flows for the three months ended April 30, 2022 and April 30, 2021 (unaudited)</a>	<a href="#">5</a>
<a href="#">Condensed notes to the interim consolidated financial statements</a>	<a href="#">6-22</a>

**Predictmedix Inc.**Condensed Interim Statements of Financial Position  
(Unaudited – expressed in Canadian dollars)

<b>ASSETS</b>	<b>April 30, 2022</b>	<b>January 31, 2022</b>
<b>CURRENT</b>		
Cash and cash equivalents	31,420	\$ 211,302
Accounts receivable (Note 16)	189,885	169,545
Sales tax receivable	230,780	211,482
Prepaid expenses (Note 6)	54,925	49,295
	<u>507,010</u>	<u>641,624</u>
Property and equipment (Note 7)	117,700	76,255
Intangible assets (Note 8)	510,178	518,778
<b>TOTAL ASSETS</b>	<b>\$ 1,134,888</b>	<b>\$ 1,236,657</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>LIABILITIES</b>		
<b>CURRENT</b>		
Accounts payable and accrued liabilities	\$ 534,926	\$ 334,452
Deferred revenue	11,720	15,220
<b>TOTAL LIABILITIES</b>	<b>\$ 546,646</b>	<b>349,672</b>
<b>SHAREHOLDERS' EQUITY</b>		
Share Capital (Note 11)	5,716,131	5,716,131
Warrant reserve (Note 11)	510,483	510,483
Share-based payment reserve (Note 10)	688,085	675,560
Accumulated deficit	(6,326,457)	(6,015,189)
<b>TOTAL SHAREHOLDERS' EQUITY</b>	<b>\$ 588,242</b>	<b>886,985</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>\$ 1,134,888</b>	<b>\$ 1,236,657</b>

Organization and nature of operations (Note 1)  
Basis of presentation and going concern (Note 2)  
Commitment and contingencies (Note 13)

Approved on behalf of the Board of Directors:

/s/ "Sheldon Kales"

Signed: Sheldon Kales, CEO and Director

/s/ "Rahul Kushwah"

Signed: Rahul Kushwah, COO and Director

The accompanying notes are an integral part of these interim condensed consolidated financial statements

**Predictmedix Inc.**Condensed Interim Consolidated Statement of Loss and Comprehensive Loss  
(Unaudited- expressed in Canadian dollars)

	For the three months ended April 30, 2022	For the three months ended April 30, 2021
<b>Revenue (Note 16)</b>	\$ 21,500	-
<b>Cost of revenue</b>	<b>8,400</b>	-
<b>Gross profit</b>	<b>13,100</b>	-
<b>Expenses:</b>		
Administration and general	\$ 10,961	\$ 5,422
Amortization (Notes 7,8)	37,253	614
Audit and accounting	-	1,750
Consulting fees	30,549	70,141
Investor relations	31,162	-
Legal fees	23,911	50,220
Management fees (Note 12)	57,900	45,900
Marketing expenses	55,676	134,280
Payroll and related	25,887	-
Rent expense (Note 12)	8,632	6,000
Share based compensation (Note 10)	12,525	83,557
Transfer agent and filing fees	19,566	4,260
Travel, entertainment and related	1,346	3,042
Vehicle use expenses (Note 12)	9,000	9,000
<b>Total operating expenses</b>	<b>(324,368)</b>	<b>(414,186)</b>
<b>Loss and comprehensive loss</b>	<b>\$ (311,268)</b>	<b>\$ (414,186)</b>
Loss per share-Basic and Diluted	\$ (0.003)	\$ (0.004)
Weighted average number of shares outstanding-Basic and Diluted	<b>109,051,292</b>	105,134,748

The accompanying notes are an integral part of these interim condensed consolidated financial statements

**Predictmedix Inc.**

Condensed Consolidated Statement of Changes in Shareholders' Equity  
for the periods ended April 30, 2022 and April 30, 2021  
(Unaudited-expressed in Canadian dollars)

	Number of common shares outstanding	Share capital	Warrant reserve	Share-based payment reserve	Deficit	Total
Balance as of January 31, 2021	101,717,973	\$ 4,031,650	\$ 115,802	\$ 853,848	\$ (4,133,011)	\$ 868,289
Private placement of units	3,114,569	634,095	455,990	-	-	1,090,085
Share issuance costs	-	(3,770)	-	-	-	(3,770)
Exercise of options	3,968,750	894,613	-	(299,300)	-	595,313
Share-based compensation	-	-	-	83,557	-	83,557
Net loss for the period	-	-	-	-	(414,186)	(414,186)
<b>Balance as at April 30, 2021</b>	<b>108,801,292</b>	<b>\$ 5,556,588</b>	<b>\$ 571,792</b>	<b>\$ 638,105</b>	<b>\$ (4,457,197)</b>	<b>\$ 2,219,288</b>
Balance as of January 31, 2022	109,051,292	\$ 5,716,131	\$ 510,483	\$ 675,560	\$ (6,015,189)	\$ 886,985
Share-based compensation	-	-	-	12,525	-	12,525
Net loss for the period	-	-	-	-	(311,268)	(311,268)
<b>Balance as at April 30, 2022</b>	<b>109,051,292</b>	<b>\$ 5,716,131</b>	<b>\$ 510,483</b>	<b>\$ 688,085</b>	<b>\$ (6,326,457)</b>	<b>\$ 588,242</b>

The accompanying notes are an integral part of these interim condensed consolidated financial statements

**Predictmedix Inc.**  
Consolidated Statement of Cash Flows  
(Unaudited-expressed in Canadian dollars)

	For the three months ended April 30, 2022	For the three months ended April 30, 2021
<b>OPERATING ACTIVITIES</b>		
Net income (loss)	\$ (311,268)	\$ (414,186)
Non-cash items included in net loss and other adjustments:		
Amortization	37,253	614
Share-based compensation	12,525	83,557
Changes in non-cash working capital:		
Sales tax receivable	(19,298)	(26,877)
Prepaid expenses	(5,630)	3,799
Accounts receivable	(20,340)	-
Accounts payable and accrued liabilities	200,474	(65,646)
Deferred revenue	(3,500)	
<b>CASH USED IN OPERATING ACTIVITIES</b>	<b>(109,784)</b>	<b>(418,739)</b>
<b>INVESTING ACTIVITIES</b>		
Purchase of property and equipment	(49,648)	-
Purchase of intangible assets	(20,450)	(41,568)
<b>CASH USED IN INVESTING ACTIVITIES</b>	<b>(70,098)</b>	<b>(41,568)</b>
<b>FINANCING ACTIVITIES</b>		
Proceeds from issuance of units	-	1,090,085
Share issue expenses	-	(3,770)
Proceeds from exercise of options	-	595,313
<b>CASH PROVIDED BY FINANCING ACTIVITIES</b>	<b>-</b>	<b>1,681,628</b>
<b>NET CHANGE IN CASH DURING THE PERIOD</b>	<b>179,882</b>	<b>1,221,321</b>
<b>CASH, BEGINNING OF PERIOD</b>	<b>211,302</b>	<b>480,051</b>
<b>CASH, END OF PERIOD</b>	<b>\$ 31,420</b>	<b>\$ 1,701,372</b>
Cash paid for interest and income taxes	\$ -	\$ -

The accompanying notes are an integral part of these interim condensed consolidated financial statements

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**1. Organization and Nature of Operations**

Admiral Bay Resources Inc. ("Admiral") was incorporated in British Columbia on September 3, 1987.

Effective September 23, 2019, Admiral was part of a three-cornered amalgamation among Admiral, 2693980 Ontario Inc. (a wholly owned subsidiary of Admiral) and Cultivar Holdings Ltd. (the "Transaction"). Admiral completed the acquisition of all the issued and outstanding shares of Cultivar Holdings Ltd. by way of a three-cornered amalgamation, pursuant to which 2693980 Ontario Inc., amalgamated with Cultivar Holdings Ltd. Pursuant to the Transaction, each registered shareholder of Cultivar Holdings Ltd. received one (1) common share in the capital of the Admiral for each common share held, resulting in the issuance of an aggregate of 97,439,900 common shares to Cultivar Holdings Ltd. Shareholders. As part of the Transaction, warrants of Cultivar Holdings Ltd. were replaced with common share purchase warrants of Admiral.

At completion of the Transaction, Admiral changed its name to Cultivar Holdings Inc. (the "Company").

On April 9, 2020, the Company announced that it has completed its name change from "Cultivar Holdings Inc." to "Predictmedix Inc." (the "Name Change"). The CUSIP number assigned to the Company's common shares following the name change is CUSIP 74040L100 (ISIN CA74040L1004). In connection with the Name Change, the Company's trading symbol, as listed on the CSE and the OTCQB have also been changed from "CULT" to "PMED", and from "CVRHF" to "PMEDF", respectively.

On February 15, 2018, the Company had acquired a 49% interest in a newly incorporated Cultivar JA Limited, ("CJA") a corporation incorporated under the laws of Jamaica. The remaining 51% interest was owned by local Jamaican business partners. On March 27, 2020, the Company sold and discontinued its interests in CJA (Note 5).

On July 16, 2018, the Company had acquired a 100% interest in a newly incorporated CannIP Holdings Inc. (formerly 2639745 Ontario Inc.) ("Cann") a corporation incorporated under the laws of the province of Ontario. Cann is engaged in the development of cosmetic and edible product lines, as well as investment in technology to detect an individual influence of cannabis. The Company did a one for one share exchange with Cann and issued 29,800,000 common shares to the shareholders of Cann.

The Company, through its subsidiaries, is in the business of investment in technology to detect if an individual is under the influence of cannabis and to predict substance addiction. The Company is currently focusing on artificial intelligence ("AI") technologies which are targeting two specific areas: 1) workplace health and safety and 2) healthcare.

The Company's corporate head office is located at 77 King Street W, Suite 3000, Toronto, Ontario, Canada, M5K 1G8.

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**2. Basis of Presentation and Going Concern****Basis of Preparation**

These condensed interim consolidated financial statements have been prepared on the historical cost basis except for financial instruments recorded at fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information. The functional currency of the Company and its subsidiaries is the Canadian dollar, which is also the Company's reporting currency.

**Statement of Compliance**

These condensed interim consolidated financial statements (the "Financial Statements") are unaudited and have been prepared on a condensed basis in accordance with International Accounting Standard 34, Interim Financial Reporting issued by the International Accounting Standards Board ("IASB"), using accounting policies of International Financial Reporting Standards ("IFRS") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by IASB and interpretations issued by IFRIC. The condensed interim consolidated financial statements should be read in conjunction with the annual consolidated financial statements for the year ended January 31, 2022, which have been prepared in accordance with IFRS, as issued by the International Accounting Standards Board ("IASB"). The unaudited condensed interim consolidated financial statements are based on accounting policies as described in the January 31, 2022 annual consolidated financial statements.

**Basis of Consolidation**

These consolidated financial statements include the accounts of the Company and its subsidiaries; Cultivar Holdings Ltd. and Cann from the date of acquisition. The Company has a 100% interest in Cann and in Cultivar Holdings Ltd. The Company had a 49% interest in CJA which was sold on March 27, 2020 (see note 5). All inter-company transactions and balances have been eliminated on consolidation.

**Going Concern Assumption**

These consolidated financial statements have been prepared using IFRS on a going concern basis, which presumes the realization of assets and discharge of liabilities in the normal course of business, for the next fiscal year. At April 30, 2022, the Company had cash of \$31,420, working capital deficit of \$39,636 and an accumulated deficit of \$6,326,457. The continuing operations of the Company are dependent on funding provided by equity investors. The Company intends to finance its future requirements through a combination of equity and/or debt issuance. There is no assurance that the Company will be able to obtain such financings or obtain them on favorable terms.

This uncertainty may cast significant doubt about the ability of the Company to continue as a going concern. These interim condensed consolidated financial statements do not include any adjustments to the carrying value or presentation of assets or liabilities that might be necessary should the Company be unable to continue as a going concern. These adjustments could be material.

## **Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

---

### **2. Basis of Presentation and Going Concern (Cont'd)** **Significant Accounting Judgments and Estimates**

The preparation of these interim consolidated financial statements in compliance with IFRS requires management to make certain critical accounting estimates and assumptions. These estimates and assumptions affect the reported amounts of assets, liabilities, shareholders' equity, and the disclosure of contingent assets and liabilities, as at the date of the financial statements, and expenses for the years reported.

#### Critical Judgements

The preparation of these interim consolidated financial statements requires management to make judgements regarding the going concern of the Company (discussed above), as well as the determination of functional currency. The functional currency is the currency of the primary economic environment in which an entity operates and has been determined for each entity within the Company. The functional currency for the Company and its subsidiaries has been determined to be the Canadian dollar.

#### Key Sources of Estimation Uncertainty

Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant.

Significant estimates made by management affecting the interim consolidated financial statements include:

#### *Share-based payments*

Estimating fair value for granted stock options requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the option, volatility, dividend yield, and rate of forfeitures and making assumptions about them.

#### *Deferred tax assets & liabilities*

The estimation of income taxes includes evaluating the recoverability of deferred tax assets and liabilities based on an assessment of the Company's ability to utilize the underlying future tax deductions against future taxable income prior to expiry of those deductions. Management assesses whether it is probable that some or all of the deferred income tax assets and liabilities will not be realized. The ultimate realization of deferred tax assets and liabilities is dependent upon the generation of future taxable income, which in turn is dependent upon the successful discovery, extraction, development and commercialization of mineral reserves. To the extent that management's assessment of the Company's ability to utilize future tax deductions changes, the Company would be required to recognize more or fewer deferred tax assets or liabilities, and deferred income tax provisions or recoveries could be affected.

#### *Useful life of property and equipment*

Property and equipment is depreciated over its estimated useful life. Estimated useful lives are determined based on current facts and past experience and takes into consideration the anticipated physical life of the asset, the potential for technological obsolescence, and regulations.

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

---

**2. Basis of Presentation and Going Concern (Cont'd)**

**Significant Accounting Judgments and Estimates (Cont'd)**

*Useful life of intangible assets*

The intangible asset is depreciated over its estimated useful life. Estimated useful lives are determined based on current facts and past experience and takes into consideration the anticipated life of the asset, the potential for technological obsolescence, and regulations.

*COVID-19 Estimation Uncertainty*

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or ability to raise funds.

**Approval of the interim consolidated financial statements**

These interim consolidated financial statements were authorized for issuance by the Board of Directors on June 29, 2022.

**3. Significant Accounting Policies**

The accounting policies set out in the consolidated financial statements at January 31, 2022, have been applied consistently to all periods presented in these condensed interim consolidated financial statements.

## Predictmedix Inc.

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

### 4. Acquisition

During the year ended January 31, 2020, the Company completed the following acquisition:

Effective September 23, 2019, the Company was part of a three-cornered amalgamation among the Company, 2693980 Ontario Inc. (a wholly owned subsidiary) and Cultivar Holdings Ltd. (the "Transaction"). The result of the transaction was that Admiral acquired all the issued and outstanding securities of Cultivar Holdings Ltd. on the basis of one share of Admiral for each share of former Cultivar. All outstanding warrants to purchase former Cultivar shares were exchanged, on an equivalent basis, for warrants to purchase shares of the Company. At completion of the transaction, Admiral changed its name to Cultivar Holdings Inc. and former Cultivar was amalgamated into 2693980 Ontario Inc.

Under IFRS, this was considered a Reverse Merger and Recapitalization (commonly referred to as a Reverse Take Over or "RTO"). The Company issued 6,514,249 shares valued at \$0.21 per share, with a total value of \$1,367,992 for the acquisition.

The fair value of the acquired assets and liabilities assumed is as follows:

---

Assets acquired by the Company:		
Cash	\$	3,448
Prepaid expenses		1,125
Liabilities assumed by the Company:		
Accounts payable and accrued liabilities		(19,127)
Loans payable		(107,525)
<hr/>		
Net liabilities assumed		(122,079)
Fair value of shares issued		(1,367,992)
<hr/>		
Loss on acquisition	\$	(1,490,071)

---

### 5. Sale of interest in Cultivar JA Limited

On March 27, 2020, the Company entered into a sale agreement (the "Sale Agreement") with respect to its 49% interest in Cultivar JA Limited ("Cultivar JA"), which holds a provisional cannabis cultivation license in Jamaica.

Pursuant to the terms of the Sale Agreement, the Company's wholly-owned subsidiary, Cultivar Holdings Ltd., agreed to sell its 49% interest in Cultivar JA and all related royalty interests to the principals of Cultivar JA in exchange for the principals of Cultivar JA agreeing to return and cancel 4,000,000 common shares of the Company owned by the principals. In addition, the principals also agreed to terminate their right to receive an additional 500,000 common shares of the Company which had been reserved for issuance upon Jamaica's Licensing Authority issuing final approval for Cultivar JA's license.

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**5. Sale of interest in Cultivar JA Limited (Cont'd)**

The sale agreement constituted a discontinued operation involving the loss of control of Cultivar JA by the Company. A discontinued operation is a component of the Company's business that represents a separate major line of business or a geographical area of operations that has been disposed of or is held for sale. Classification as a discontinued operation occurs upon disposal or earlier if the operation meets the criteria to be classified as held for sale. When an operation is classified as a discontinued operation the comparative statement of comprehensive loss and cash flow operation is re-presented as if the operation had been discontinued from the start of the comparative period.

The sale agreement constituted a discontinued operation of the Company effective March 27, 2020. As a result, all the assets and liabilities of Cultivar JA have been removed from the statement of financial position of the Company. The cancellation of 4,000,000 shares of the Company have been valued at \$540,000, being the fair value of the shares on the date of the sale transaction.

The expenses of Cultivar JA have been determined to be a discontinued operation by the Company, and as a result, have been disclosed separately on the statement of income (loss) and comprehensive income (loss)

	For the three months ended April 30, 2022	For the three months ended April 30, 2021
<b>Expenses:</b>		
Amortization	\$ -	\$ -
Interest expense	-	-
Travel, entertainment and related	-	-
<b>Net loss for the period prior to the sale transaction</b>	-	-
Gain on divestiture	-	-
Gain (Loss) from discontinued operations, net of tax	\$ -	\$ -

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**6. Prepaid Expenses**

Prepaid expenses as of April 30, 2022 include \$nil (January 31, 2022: \$nil) to conduct a study to further validate its proprietary impairment detection technology for both alcohol and cannabis.

**7. Property and Equipment**

	<b>Equipment</b>		<b>Leasehold Improvement</b>		<b>Total</b>
<b>Cost</b>					
Balance as at January 31, 2021	\$ 13,368	\$	-	\$	13,368
Additions	84,755		-		84,755
Balance as at January 31, 2022	\$ 98,123	\$	-	\$	98,123
Additions	49,648		-		49,648
Balance as at April 30, 2022	\$ 147,771	\$	-	\$	147,771
<b>Accumulated Amortization</b>					
Balance as at January 31, 2021	\$ 5,180	\$	-	\$	5,180
Amortization	16,688		-		16,688
Balance as at January 31, 2022	\$ 21,868	\$	-	\$	21,868
Amortization	8,203		-		8,203
Balance as at April 30, 2022	\$ 30,071	\$	-	\$	30,071
<b>Net Carrying Amounts</b>					
<b>As at April 30, 2022</b>	<b>\$ 117,700</b>	<b>\$</b>	<b>-</b>	<b>\$</b>	<b>117,700</b>
<b>As at January 31, 2022</b>	<b>\$ 76,255</b>	<b>\$</b>	<b>-</b>	<b>\$</b>	<b>76,255</b>

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**8. Intangible Assets**

a) On July 21, 2020, the Company completed the acquisition of MobileWellbeing ("MWB"), an innovative, feature rich, Telemedicine Remote Patient Monitoring platform that will integrate with the Company's Artificial Intelligence ("AI") driven rapid screening system for infectious diseases, including COVID-19.

The consideration for the purchase was satisfied by payment in cash for \$25,000, issuance of 20,000 shares and additional 30,000 shares to be issued on the 90<sup>th</sup> day of close. Consideration paid in the form of equity instruments is being considered share-based payment within the scope of IFRS 2 Share-based Payment and this asset acquisition is fair valued for a total consideration for \$78,000 at the point control was obtained.

The acquisition has contingent considerations and royalty payments on achievement of certain milestones. The Company shall pay royalty of 20 percent of gross sales from the first \$2.5 million in sales generated exclusively from the MWB platform. In addition, the Company is obligated to issue an additional 200,000 common shares commencing with the release of the initial version of the MWB platforms to the market and achievement of sales related milestones.

Contingent consideration in an asset acquisition was discussed at the March 2016 IFRS Interpretations Committee (IFRIC) meeting. An accounting policy choice exists, therefore an entity may recognize a liability for the expected variable payments at the time control of the underlying asset is obtained or they may only recognize such a liability as the related activity that gives rise to the variability occurs. The Company has opted to recognize the liability only when the related activity that gives rise to the variability occurs.

<b>Consideration</b>	
Cash consideration on closing	\$ 25,000
Issued shares (50,000 shares issued at \$1.06/share)	53,000
	<b>\$ 78,000</b>

  

<b>Purchase Price allocation</b>	
Intangible asset- MWB remote patient monitoring platform	\$ 78,000
	<b>\$ 78,000</b>

b) The Company's other intangible asset relates to the development of infectious disease symptom screening solution ("IDSS").

The Company has commenced amortization on the intangible assets on a straight-line basis over the useful life estimated to be for 5 years.

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**8. Intangible Assets (Cont'd)**

The Company's intangible assets are comprised of the following:

		<b>MWB</b>		<b>IDSS</b>		<b>Total</b>
<b><u>Cost</u></b>						
<b>Balance at January 31, 2021</b>	<b>\$</b>	<b>91,970</b>	<b>\$</b>	<b>156,040</b>	<b>\$</b>	<b>248,010</b>
Additions		46,591		286,778		333,369
<b>Balance at January 31, 2022</b>	<b>\$</b>	<b>138,561</b>	<b>\$</b>	<b>442,818</b>	<b>\$</b>	<b>581,379</b>
Additions		-		20,450		20,450
<b>Balance at April 30, 2022</b>	<b>\$</b>	<b>138,561</b>	<b>\$</b>	<b>463,268</b>	<b>\$</b>	<b>601,829</b>
<b>Accumulated amortization:</b>						
<b>Balance as at January 1, 2021</b>	<b>\$</b>	<b>-</b>	<b>\$</b>	<b>-</b>	<b>\$</b>	<b>-</b>
Amortization		18,990		43,611		62,601
<b>Balance as at January 31, 2022</b>	<b>\$</b>	<b>18,990</b>	<b>\$</b>	<b>43,611</b>	<b>\$</b>	<b>62,601</b>
Amortization		6,756		22,294		29,050
<b>Balance as at April 30, 2022</b>	<b>\$</b>	<b>25,746</b>	<b>\$</b>	<b>65,905</b>	<b>\$</b>	<b>91,651</b>
<b><u>Net Book Value</u></b>						
<b>Balance, April 30, 2022</b>	<b>\$</b>	<b>112,815</b>	<b>\$</b>	<b>397,363</b>	<b>\$</b>	<b>510,178</b>
<b>Balance, January 31, 2022</b>	<b>\$</b>	<b>119,571</b>	<b>\$</b>	<b>399,207</b>	<b>\$</b>	<b>518,778</b>

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**9. Leases**

Right-of-use assets of \$nil (January 31, 2022- \$nil) and total lease liability of \$nil (January 31, 2022- \$nil) have been removed from the statement of financial position of the Company as of January 31, 2021 on account of the sale of Company's interest in Cultivar JA (Note 5).

**Right of use assets**

The Company's right of use assets as at April 30, 2022 and January 31, 2022 were as follows:

Balance as at January 31, 2020	<b>\$ 12,192</b>
Amortization	<b>(2,871)</b>
Discontinuance of business	<b>(9,321)</b>
As at April 30, 2022 and January 31, 2022	<b>\$ -</b>

**Lease liability**

At the commencement date of the leases, the lease liability was measured at the present value of the lease payments that were not paid at that date. The lease payments are discounted using an interest rate of 18% which is the Company incremental borrowing rate.

Lease liability interest expense recognized in profit and loss and lease payments recognized in the financing component of statement of cash flows are as follows:

Balance as at January 31, 2020	<b>\$ 15,189</b>
Interest expense	<b>687</b>
Lease payments made during the year	<b>(2,129)</b>
Discontinuance of business	<b>(13,747)</b>
As at April 30, 2022 and January 31, 2022	<b>\$ -</b>

The Company's lease liability as at April 30, 2022 and January 31, 2022 was as follows:

	<b>April 30, 2022</b>	<b>January 31, 2022</b>
Lease liability - current	\$ -	\$ -
Lease liability – non- current	-	-
Total lease liability	<b>\$ -</b>	<b>\$ -</b>

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**10. Stock-Based Compensation**

The Company has established a stock option plan whereby officers, directors, employees and service providers may be granted options to purchase common shares at a fixed price. Vesting and expiry provisions are determined at the date of grant. The plan provides for the issuance of stock options to acquire up to 10% of the Company's issued and outstanding capital. The plan is a rolling plan as the number of shares reserved for issuance pursuant to the grant of stock options will increase as the Company's issued and outstanding share capital increases.

Year ended January 31, 2022

- (a) The Company expensed \$34,246 relating to the vesting of options issued on July 17, 2020, resulting in unvested stock-based compensation expense of \$nil as of January 31, 2022.
- (b) The Company expensed \$18,958 relating to the vesting of options issued on September 21, 2020, resulting in unvested stock-based compensation expense of \$nil as of January 31, 2022.
- (c) On March 23, 2021, the Company granted options to a consultant to purchase up to 250,000 common shares. These options were issued at an exercise price of \$0.36 per share and vest equally over the next 3, 6, 9 and 12 months. These options have a term of one (1) year expiring on March 23, 2022. The fair value of each option used for the purpose of estimating the stock-based compensation is estimated using the Black-Scholes option pricing model with the following assumptions:

Risk free rate	0.26%
Expected dividends	0%
Expected forfeiture rate	0%
Expected volatility	134.3%
Expected life	1 year
Unvested stock-based compensation expense as of January 31, 2022	\$ 1,834

During the year ended January 31, 2022, the Company expensed \$50,675 relating to the vesting of options, resulting in unvested stock-based compensation expense of \$1,834 as of January 31, 2022.

- (d) On June 9, 2021, the Company granted options to a consultant to purchase up to 250,000 common shares. These options were issued at an exercise price of \$0.345 per share and vest equally over the next 3, 6, 9 and 12 months. These options have a term of 18 months expiring on December 9, 2022. The fair value of each option used for the purpose of estimating the stock-based compensation is estimated using the Black-Scholes option pricing model with the following assumptions:

Risk free rate	0.32%
Expected dividends	0%
Expected forfeiture rate	0%
Expected volatility	146.38%
Expected life	1.5 years
Unvested stock-based compensation expense as of January 31, 2022	\$ 6,778

During the year ended January 31, 2022, the Company expensed \$48,672 relating to the vesting of options, resulting in unvested stock-based compensation expense of \$6,778 as of January 31, 2022.

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**10. Stock-Based Compensation (Cont'd)**Year ended January 31, 2022 (Cont'd)

- (e) On July 30, 2021, the Company granted options to a consultant to purchase up to 250,000 common shares. These options were issued at an exercise price of \$0.25 per share and vest equally over the next 3, 6, 9 and 12 months. These options have a term of 18 months expiring on January 30, 2023. The fair value of each option used for the purpose of estimating the stock-based compensation is estimated using the Black-Scholes option pricing model with the following assumptions:

Risk free rate	0.38%
Expected dividends	0%
Expected forfeiture rate	0%
Expected volatility	131.33%
Expected life	1.5 years
Unvested stock-based compensation expense as of January 31, 2022	\$ 7,826

During the year ended January 31, 2022, the Company expensed \$30,445 relating to the vesting of options, resulting in unvested stock-based compensation expense of \$7,826 as of January 31, 2022.

As of January 31, 2022, there was a total of \$16,438 of unvested stock-based compensation expense.

Three- month period ended April 30, 2022

- (a) The Company expensed \$1,834 relating to the vesting of options issued on March 23, 2021, resulting in unvested stock-based compensation expense of \$nil as of April 30, 2022.
- (b) The Company expensed \$6,778 relating to the vesting of options issued on June 9, 2021, resulting in unvested stock-based compensation expense of \$nil as of April 30, 2022.
- (c) The Company expensed \$3,913 relating to the vesting of options issued on July 30, 2021, resulting in unvested stock-based compensation expense of \$3,913 as of April 30, 2022.

As of April 30, 2022, there was a total of \$3,913 of unvested stock-based compensation expense.

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**10. Stock-Based Compensation (Cont'd)**

Continuity of the Company's options is as follows:

	Number of Options	Weighted Average Exercise Price
Outstanding, January 31, 2022	1,100,000	\$0.42
Expired	(70,000)	\$0.54
Expired	(200,000)	\$0.54
Expired	(250,000)	\$0.36
Outstanding, April 30, 2022	580,000	\$0.40

As at April 30, 2022, the Company had the following share purchase options outstanding and exercisable:

Outstanding	Exercisable	Exercise Price	Remaining Life (Years)	Expiry Date
80,000	80,000	\$1.02	3.21	July 17, 2025
250,000	187,500	\$0.35	0.61	December 9, 2022
250,000	187,500	\$0.25	1.25	July 30, 2023
580,000	455,000	\$0.40	1.24	

**11. Capital Stock**

The Company is authorized to issue the following shares:

- Unlimited number of common shares without par value

**a) Common shares**

The holders of common shares are entitled to receive dividends which are declared from time to time and are entitled to one vote per share at meetings of the Company. All shares are ranked equally with regards to the Company's residual assets.

At April 30, 2022, the Company has 109,051,292 common shares issued and outstanding.

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**11. Capital Stock (Cont'd)****b) Share issuances**During the three- month period ended April 30, 2022

The Company did not issue any stock during the three months ended April 30, 2022.

During the year ended January 31, 2022

- On March 5, 2021, the Company closed a private placement of 3,114,569 units at \$0.35 per unit for a consideration of \$1,090,085. Each unit is comprised of one common share and one common share purchase warrant, with each warrant exercisable into a common share of the Company at an exercise price of \$0.50 per share for a period of 24 months. The Black-Scholes option pricing model was used to determine the fair value of the warrants using the following weight average assumptions: Expected dividend yield of 0%; risk free interest rate of 0.29%; expected volatility of 131%; expected life of 2 years. The relative fair value of the warrants has been valued at \$394,681 and common shares at \$695,404. In connection with this private placement, the Company incurred \$3,770 in share issuance costs.
- 3,968,750 shares were issued upon exercise of 3,968,750 options at a price of \$0.15 per share for total gross proceeds of \$595,313. An amount of \$361,284 was reclassified from share-based payment reserve to share capital.
- 250,000 shares were fair valued at \$36,250 and issued for services.

**c) Warrants**

Continuity of the Company's warrants is as follows:

	Number of Warrants	Weighted Average Exercise Price
Outstanding, January 31, 2020	1,648,000	\$0.50
Exercised	(100,000)	\$0.50
Outstanding, January 31, 2021	1,548,000	\$0.50
Issued	3,114,569	\$0.50
Expired	(1,548,000)	\$0.50
Outstanding, April 30, 2022 and January 31, 2022	3,114,569	\$0.50

As at April 30, 2022, the Company had the following warrants outstanding:

Outstanding	Exercise Price	Remaining Life (Years)	Expiry Date
3,114,569	\$0.50	0.84	March 5, 2023

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**12. Related Party Transactions**

Related parties include key management personnel, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. Key management of the Company are members of the Board of Directors, the Chief Executive Officer (“CEO”), the Chief Financial Officer (“CFO”) and the Chief Operating Officer (“COO”). Transactions with key management personnel not disclosed elsewhere in the financial statements include the following:

	<b>Three months ended April 30, 2022</b>		<b>Three months ended April 30, 2021</b>	
Management fees to the CEO	\$	30,000	\$	25,500
Management fees to the COO		25,500		18,000
Management fees to the CFO		2,400		2,400
Total Management fees	\$	57,900	\$	45,900
Vehicle expense to the CEO		4,500		4,500
Vehicle expense to the COO		4,500		4,500
Rent to the CEO included in rent expense		6,000		6,000
	\$	72,900	\$	60,900

During the three months ended April 30, 2022, the Company expensed \$36,000 (April 30, 2021: \$21,000) being marketing expenses to companies controlled by the children of the CEO.

As of April 30, 2022, there was \$94,463 due to related parties (April 30, 2021- \$nil).

**13. Commitments and Contingencies**

Effective July 1, 2020, the Company signed a two-year contract with a corporation owned and controlled by the CEO to pay monthly compensation of \$8,500 for CEO services which effective September 1, 2021 was revised to \$10,000 per month. In addition, the Company is obligated to pay monthly rent for \$2,000 and an additional \$1,500 for the use of a personal vehicle.

Effective July 1, 2020, the Company signed a two-year contract with a corporation owned and controlled by the COO to pay monthly compensation of \$6,000 for COO services which effective May 1, 2021, is revised to \$8,500 per month. In addition, the Company is obligated to pay an additional \$1,500 for the use of a personal vehicle.

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**14. Financial Instruments**

The fair value of the Company's accounts receivables and accounts payable, approximate carrying value, due to their short-term nature. The Company's cash is measured at fair value under the fair value hierarchy based on level one quoted prices in active markets for identical assets or liabilities.

**Financial risk management and objectives**

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk, and market risk (including interest rate risk, foreign currency risk, and commodity price risk).

The Company thoroughly examines the various financial risks to which it is exposed and assesses the impact and likelihood of those risks. Where material, these risks are reviewed and monitored by the Board of Directors.

Credit risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk as during the period ended April 30, 2022, one customer represented 100% of the total revenue and represented 100% of the total accounts receivable.

Liquidity risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if its access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or matters specific to the Company. The Company historically has generated cash flows primarily from its financing activities.

The Company manages its liquidity needs by carefully monitoring scheduled costs. Liquidity is measured in various time bands, on day to day and week-to-week basis, as well as on long term liquidity needs over 180 day to 360 day look out periods. Funding for long term liquidity needs is based on the ability of the Company to successfully complete private placements.

As at April 30, 2022, the Company had cash and cash equivalents of \$31,420 to settle current liabilities of \$546,646.

**Predictmedix Inc.**

Notes to Interim Condensed Consolidated Financial Statements

April 30, 2022

(in Canadian dollars)

(Unaudited)

**14. Financial Instruments (Cont'd)**Market Risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, commodity and equity prices, and foreign exchange rates.

*(a) Interest rate risk*

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk.

*(b) Price risk*

The Company is not exposed to significant price risk as it does not possess investments in publicly traded securities.

*(c) Currency risk*

Currency risk is the risk that the fair value of future cash flows of a financial instrument denominated in a foreign currency will fluctuate because of changes in foreign exchange rates. Effective sale of the Company's interest in Cultivar JA in March 2020, the Company has no exposure to any currency except Canadian dollars.

**15. Capital Management**

The Company considers its capital to be shareholders' equity, which is comprised of share capital and deficit, which as at April 30, 2022 totaled \$588,242. The Company's capital structure is adjusted based on the funds available to the Company such that it may continue to seek new opportunities. The Board of Directors does not establish quantitative return on capital criteria, but rather relies on the expertise of management and other professionals to sustain future development of the business.

The sources of future funds presently available to the Company are through the sale of equity capital or debt of the Company. The ability of the Company to arrange such financing in the future will depend in part upon the prevailing capital market conditions as well as the business performance of the Company. There can be no assurance that the Company will be successful in its efforts to arrange additional financing, if needed, on terms satisfactory to the Company.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. The Company is not subject to externally imposed capital restrictions.

**16. Business Segment and Concentration**

The Company, through its subsidiaries, is currently focused on artificial intelligence ("AI") technologies which are targeting two specific areas: 1) workplace health and safety and 2) healthcare. All assets are located in Canada except property and equipment for \$70,965 which is located in India.

During the three months ended April 30, 2022, one customer represented 100% of the total revenue and represented 100% of the total accounts receivable.